Stocktoria
Atara Biotherapeutics, Inc. ATRA
Atara Biotherapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — |
| R&D expense | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M | $167.5M | $81.2M | $56.5M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M | -$309.1M | -$295.7M | -$237.1M | -$121.5M | -$81.2M |
| Interest expense | $3.8M | $4.6M | $5.3M | $373,000 | — | — | — | — | — | — |
| Income tax | $31,000 | -$12,000 | $15,000 | $12,000 | $46,000 | $15,000 | $12,000 | -$44,000 | -$14,000 | $10,000 |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M | -$306.6M | -$291.0M | -$230.7M | -$119.5M | -$79.0M |
| EPS (diluted) | $2.57 | $-11.41 | $-65.19 | $-2.24 | $-3.63 | $-4.15 | — | — | — | — |
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M | -$180.8M | -$235.6M | -$179.8M | -$87.5M | -$60.0M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M | -$185.3M | -$241.4M | -$215.7M | -$107.7M | -$63.0M |
| Cash & equivalents | $8.5M | $25.0M | $25.8M | $92.9M | $106.1M | $200.4M | $74.3M | $60.7M | $79.2M | $48.0M |
| Inventory | $0 | $10.7M | $9.7M | $1.6M | $0 | — | — | — | — | — |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M | $588.1M | $342.9M | $391.8M | $217.8M | $263.9M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M | $125.8M | $52.2M | $53.0M | $39.9M | $10.2M |
| Shareholders' equity | -$38.5M | -$97.3M | $99.2M | $126.6M | $279.6M | $462.3M | $290.8M | $339.2M | $177.9M | $253.7M |
Growth · year-over-year · Revenue CAGR 23.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.3% | +1404.0% | -86.5% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.